GLP1R and metabolic dysfunction-associated steatohepatitis: Survodutide: A dual agonist of glucagon and GLP-1 receptors, survodutide has shown potential benefits in metabolic dysfunction-associated steatohepatitis (MASH), including improving fatty acid oxidation, reducing lipogenesis, and suppressing hepatic inflammation.